SMITHKLINE BEECHAM CORPORATION Patent applications |
Patent application number | Title | Published |
20120045774 | Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA | 02-23-2012 |
20110144167 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) | 06-16-2011 |
20110053972 | INHIBITORS OF AKT ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 03-03-2011 |
20110034507 | FARNESOID X RECEPTOR AGONISTS - The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome. | 02-10-2011 |
20100330535 | Chemo-mechanical Polishing of Dentures - This disclosure relates to a composition and method for cleaning and polishing dentures during denture fabrication. | 12-30-2010 |
20100323329 | Apparatus and Method for Manufacturing Customized Dentures - This disclosure relates to an apparatus and method for digitally utilizing and customizing dental features needed in the manufacture of dentures. | 12-23-2010 |
20100311775 | Novel sEH Inhibitors and Their Use - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: | 12-09-2010 |
20100273661 | Methods and Kits for Predicting Treatment Response in Type II Diabetes Mellitus Patients - A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine. Also provided are kits useful for the methods of the invention. | 10-28-2010 |
20100272743 | Staphylococcus epidermidis nucleic acids and proteins - polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from | 10-28-2010 |
20100267759 | INHIBITORS OF Akt ACTIVITY - Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 10-21-2010 |
20100249179 | Farnesoid X Receptor Agonists - The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same. | 09-30-2010 |
20100240642 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators - The present invention relates to certain indole derivatives that are modulators of PPARγ, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. | 09-23-2010 |
20100227856 | NOVEL COMPOUNDS - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperidines, according to Formula I | 09-09-2010 |
20100210706 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS - The present invention relates to a compound represented by the following formula: | 08-19-2010 |
20100196310 | METHODS OF TREATING CANCER BY ADMINISTERING HUMAN IL-18 COMBINATIONS - The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents. | 08-05-2010 |
20100168122 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS - The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial | 07-01-2010 |
20100168100 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 07-01-2010 |
20100160209 | Composition and Method for Increasing Cell Permeability of a Compound - The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and/or metabolic syndrome. | 06-24-2010 |
20100120799 | PURINE DERIVATIVES AS IMMUNOMODULATORS - Compounds of formula (I): | 05-13-2010 |
20100120775 | Farnesoid X Receptor Agonists - The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same. | 05-13-2010 |
20100105767 | COMPOUNDS, COMPOSITIONS AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed. | 04-29-2010 |
20100105749 | CHEMICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS - The present invention provides compounds of the formulae (I) and (II), and derivatives thereof, for the treatment of cardiovascular conditions | 04-29-2010 |
20100105712 | CHEMICAL COMPOUNDS - Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. | 04-29-2010 |
20100086554 | METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES - The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain. | 04-08-2010 |
20100086547 | METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES - The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 μg/mL, an Area Under the Curve value of at least about 15.5±2.7 μg/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days. | 04-08-2010 |
20100081792 | Ligand - The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target. | 04-01-2010 |
20100075995 | COMPOUNDS - Compounds of formula (I): | 03-25-2010 |
20100069453 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 03-18-2010 |
20100056760 | SIALOADHESIN FACTOR-2 ANTIBODIES - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents. | 03-04-2010 |
20100050770 | APPARATUS AND METHOD FOR MEASURING THE ACCELERATION IMPARTED ON METERED DOSE DELIVERY CONTAINERS - An apparatus comprises a main body member; and a transducer in communication with the main body member, the transducer adapted to receive an acceleration force imparted to the main body member. A method for assessing acceleration forces imparted to an apparatus comprises a main body member and transducer in communication with the main body member, the transducer adapted to receive the external acceleration force imparted to the main body member, wherein the transducer converts the acceleration forces to electrical signals and the acceleration forces are accessed. | 03-04-2010 |
20100029782 | Calcilytic Compounds - Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided. | 02-04-2010 |
20100016318 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE - The present invention relates to a compound represented by the following formula: | 01-21-2010 |
20100010022 | CANCER TREATMENT METHOD - A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same. | 01-14-2010 |
20090318472 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS - The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity. | 12-24-2009 |
20090312365 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 12-17-2009 |
20090306127 | Certain Chemical Entities, Compositions and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 12-10-2009 |
20090291442 | HSPA1A AS A MARKER FOR SENSITIVITY TO KSP INHIBITORS - The present invention relates to methods for predicting a response to treatment with a kinesin spindle protein inhibitor using heat shock protein 70, isoform A1a, also known as HSPA1a, as a marker for sensitivity to the kinesin spindle protein (KSP) inhibitors. Method are provided for predicting a response to treatment with a kinesin spindle protein inhibitor of a first mammal in need thereof comprising determining an amount of HSPA1a mRNA transcript produced by said first mammal, wherein the amount of said HSPA1a mRNA transcript produced by said first mammal is indicative of said mammal's sensitivity to said kinesin spindle protein inhibitor | 11-26-2009 |
20090286841 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 11-19-2009 |
20090264482 | CHEMICAL COMPOUNDS - This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds. | 10-22-2009 |
20090253648 | Tricyclic-Nucleoside Compounds for Treating Viral Infections - Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus. | 10-08-2009 |
20090239866 | PEPTIDE DEFORMYLASE INHIBITORS - Novel PDF inhibitors and novel methods for their use are provided. | 09-24-2009 |
20090215818 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using thiozolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiozolidinedione derivatives. | 08-27-2009 |
20090208457 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections - Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. | 08-20-2009 |
20090203012 | Metabolic Syndrome Genetics - A gene (and polymorphisms within it) was associated with multiple components of the metabolic syndrome. Methods of screening subjects to identify risk of metabolic syndrome and related conditions are described, as are methods of screening compounds to identify those that act on the gene product as a target for the treatment of these conditions. | 08-13-2009 |
20090192189 | TREATMENT OF CANCERS EXPRESSING P95 ERBB2 - The truncated ErbB2 receptor (p95 | 07-30-2009 |
20090176746 | THROMBOPOIETIN MIMETICS - Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | 07-09-2009 |
20090170907 | Chemical Compounds - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 07-02-2009 |
20090170871 | IL-8 Receptor Antagonists - This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). | 07-02-2009 |
20090170848 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones. | 07-02-2009 |
20090163588 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 06-25-2009 |
20090159841 | Recovery of Optically Active Epoxy Alcohols - A process to recover optically active epoxy alcohols from asymmetric epoxidation reaction mixtures such as those produced using the Sharpless method of epoxidation of allylic alcohols. The process includes adding a reducing agent to reduce an organic hydroperoxide in the asymmetric epoxidation reaction product to a corresponding alcohol to form a reduced epoxidation reaction mixture; adding the reduced reaction product to a film evaporation unit to form a residue fraction and an optically active epoxy alcohol distillate fraction; and distilling the optically active epoxy alcohol distillate fraction to purify the optically active epoxy alcohol. | 06-25-2009 |
20090131458 | Compounds - The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants. | 05-21-2009 |
20090098129 | Member of the TNF Ligand Family - The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of figure ( | 04-16-2009 |
20090093451 | IL-8 Receptor Antagonists - This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). | 04-09-2009 |
20090069302 | CHEMICAL COMPOUNDS - The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same. | 03-12-2009 |
20090062307 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS - The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity. | 03-05-2009 |
20090017020 | RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS - Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. | 01-15-2009 |
20090012133 | Polymorphic Form of -Acetic Acid - The present invention relates to a novel polymorphic form of the compound {2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylthio]phenoxy}-acetic acid, methods of preparing it, pharmaceutical compositions and medicaments containing the same, and use of such polymorphs, compositions and medicaments in the treatment of PPAR mediated diseases or conditions. | 01-08-2009 |
20090012011 | Novel Compounds - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted pyrrolidines, according to Formula I | 01-08-2009 |
20090005580 | Compounds, compositions and methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed. | 01-01-2009 |
20080306355 | Method and System for Monitoring Gastrointestinal Function and Physiological Characteristics - A system and method for evaluating gastrointestinal motility and, optionally, other physiological characteristics (e.g., pulse rate) that can be effectively employed to acquire one or more signals associated with acoustic energy (i.e. sound) emanating from an abdominal region of a body and determine at least one gastrointestinal parameter or event based on the acoustic energy signal(s) is described. The gastrointestinal parameter can include a gastrointestinal event, including gastrointestinal mixing, emptying, contraction and propulsion, and gastrointestinal transit time, or a gastrointestinal system disorder, including reflux disease, irritable bowel disease, ulcerative colitis, constipation, diarrhea, and a migrating motor complex disorder. | 12-11-2008 |
20080306278 | PROCESS - An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors). | 12-11-2008 |
20080293716 | Chemical Compounds - There is provided a compound of Formula (I) or a salt, solvate, or physiologically functional derivative thereof: | 11-27-2008 |
20080269200 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors - Indole carboxamide compounds of Formula (I): | 10-30-2008 |
20080261945 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine - The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: | 10-23-2008 |
20080255182 | Certain chemical entities, compositions, and methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 10-16-2008 |
20080255143 | Inhibitors of Akt Activity - Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 10-16-2008 |
20080255124 | Chemical Compounds - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 10-16-2008 |
20080213212 | Sialoadhesin factor-2 antibodies - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents | 09-04-2008 |